{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.1","value":"21.9"},{"groupId":"OG001","spread":"8.41","value":"19.6"}]}],"title":"DOR by Modified 3rd IWWM criteria"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.11","value":"21.7"},{"groupId":"OG001","spread":"8.45","value":"19.5"}]}],"title":"DOR by 6th IWWM Criteria"}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"DOR is defined as the interval from the first documentation of Complete Response (CR), Very Good Partial Response (VGPR), Partial Response (PR) or Minor Response (MR) to the earlier of the first documentation of definitive PD or death from any cause. The summary statistics are provided for DOR.","dispersionType":"Standard Deviation","groups":[{"description":"100 mg BID N=87 + 200 mg QD N= 5","id":"OG000","title":"Previously Treated (N=92)"},{"description":"100 mg BID N= 13 + 200 mg QD N=1","id":"OG001","title":"Treatment Naive (N=14)"}],"paramType":"MEAN","populationDescription":"In the original protocol, previously treated subjects were planned to be randomized 1:1 into 2 cohorts: Cohort 1 to receive Acala 100 mg BID for 28 days and Cohort 2 to receive Acala 200 mg once daily (QD) for 28 days. After enrollment started, the dose regimen was amended. The 200 mg QD dose was eliminated, and subjects who were enrolled under the original protocol and received treatment with 200 mg QD were switched to 100 mg BID. Results are combined.","reportingStatus":"POSTED","timeFrame":"Primary analysis occur when all subjects have completed Cycle 27 or have exit the study","title":"Summary of Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}